Are there any financial requirements for the kadcyla patient assistance?

How much does Kadcyla cost without assistance?

Kadcyla (ado-trastuzumab emtansine) costs roughly $15,000–$17,000 per dose when billed to insurance or for cash-pay patients. The drug is typically given every three weeks, so annual costs often reach $250,000 or above.

What financial documents are needed for the Genentech patient assistance program?

Patients must submit proof of U.S. residency, income documentation such as tax returns or pay stubs, and current insurance information. Applications require a prescription from a healthcare provider and the provider’s NPI number.

Does the Kadcyla patient assistance program cover the drug cost completely?

The Genentech Access Solutions program covers the drug itself for eligible patients. It does not cover administration fees, infusion-center charges, or office visit costs.

When does the Kadcyla patent expire?

Kadcyla’s primary patent expires in 2029. Biosimilars are unlikely to reach the market before then.

Can uninsured patients receive Kadcyla through the assistance program?

Uninsured patients who meet income limits are eligible for the free drug program. They still need a prescribing physician to enroll them in Genentech Access Solutions.

What alternative ways exist to afford Kadcyla?

Co-pay assistance cards from Genentech can reduce out-of-pocket costs for commercially insured patients to $0 per dose. State Medicaid programs and local cancer foundations sometimes cover the drug or provide additional support.